Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Charles

Showing results (11-20 of 85) with videos related to

Pageof 9
Sort By:
Clinical Cardiology|May 21, 2020
Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A retrospective studySangmee Sharon Bae, Buzand Oganesian, Ilana Golub, et al.
Rheumatology International|August 2, 2011
An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapyStephanie A Kovalchik, Christina Charles-Schoeman, Dinesh Khanna, et al.
Clinical Rheumatology|September 22, 2022
Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritisAmir A Razmjou, Jennifer M Wang, Ani Shahbazian, et al.
Clinical Rheumatology|November 13, 2017
High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritisChristina Charles-Schoeman, David Meriwether, Yuen Yin Lee, et al.
Clinical Rheumatology|September 14, 2023
Correction to: Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritisAmir A Razmjou, Jennifer M Wang, Ani Shahbazian, et al.
Medicine|January 12, 2021
Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study")Rohit Aggarwal, Christina Charles-Schoeman, Joachim Schessl, et al.
The Journal of Rheumatology|July 15, 2023
Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving TofacitinibChristina Charles-Schoeman, Craig Hyde, Shunjie Guan, et al.
ACR Open Rheumatology|May 26, 2022
Altered Gut Microbiome in Patients With DermatomyositisSangmee Sharon Bae, Tien S Dong, Jennifer Wang, et al.
Rheumatology and Therapy|November 14, 2025
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United StatesChristina Charles-Schoeman, Patrick Zueger, Erin McDearmon-Blondell, et al.
The American Journal of Medicine|August 20, 2020
Major Lipids and Future Risk of Pneumonia: 20-Year Observation of the Atherosclerosis Risk in Communities (ARIC) Study CohortSangmee Sharon Bae, L Cindy Chang, Sharon Stein Merkin, et al.
Pageof 9

Showing results (11-20 of 85) with videos related to

Sort By:
Pageof 9
Clinical Cardiology|May 21, 2020
Statin use in patients with non-HMGCR idiopathic inflammatory myopathies: A retrospective studySangmee Sharon Bae, Buzand Oganesian, Ilana Golub, et al.
Rheumatology International|August 2, 2011
An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapyStephanie A Kovalchik, Christina Charles-Schoeman, Dinesh Khanna, et al.
Clinical Rheumatology|September 22, 2022
Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritisAmir A Razmjou, Jennifer M Wang, Ani Shahbazian, et al.
Clinical Rheumatology|November 13, 2017
High levels of oxidized fatty acids in HDL are associated with impaired HDL function in patients with active rheumatoid arthritisChristina Charles-Schoeman, David Meriwether, Yuen Yin Lee, et al.
Clinical Rheumatology|September 14, 2023
Correction to: Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritisAmir A Razmjou, Jennifer M Wang, Ani Shahbazian, et al.
Medicine|January 12, 2021
Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study")Rohit Aggarwal, Christina Charles-Schoeman, Joachim Schessl, et al.
The Journal of Rheumatology|July 15, 2023
Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving TofacitinibChristina Charles-Schoeman, Craig Hyde, Shunjie Guan, et al.
ACR Open Rheumatology|May 26, 2022
Altered Gut Microbiome in Patients With DermatomyositisSangmee Sharon Bae, Tien S Dong, Jennifer Wang, et al.
Rheumatology and Therapy|November 14, 2025
Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United StatesChristina Charles-Schoeman, Patrick Zueger, Erin McDearmon-Blondell, et al.
The American Journal of Medicine|August 20, 2020
Major Lipids and Future Risk of Pneumonia: 20-Year Observation of the Atherosclerosis Risk in Communities (ARIC) Study CohortSangmee Sharon Bae, L Cindy Chang, Sharon Stein Merkin, et al.
Pageof 9